{"id":61800,"date":"2026-03-30T14:44:35","date_gmt":"2026-03-30T06:44:35","guid":{"rendered":"https:\/\/flcube.com\/?p=61800"},"modified":"2026-03-30T14:44:36","modified_gmt":"2026-03-30T06:44:36","slug":"insilico-medicine-reports-56-2m-revenue-in-2025-amid-strategic-pipeline-buildout-cash-reserves-stand-at-393m","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61800","title":{"rendered":"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M"},"content":{"rendered":"\n<p><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>), a pioneer in <strong>generative AI-driven drug discovery<\/strong>, released its 2025 financial results, reporting <strong>$56.2 million in total revenue<\/strong>, a <strong>34.5% year-over-year decline<\/strong>, offset by robust cash reserves and continued pipeline advancement. Despite the revenue contraction, the company highlighted that its <strong>Pharma.AI platform has generated over 20 clinical- or IND-stage assets<\/strong>, with <strong>seven licensed deals totaling up to $2.17 billion<\/strong> in potential value.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025<\/th><th>2024<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>$56.2M<\/td><td>$85.8M<\/td><td>\u219334.5%<\/td><\/tr><tr><td>\u2014 Drug Discovery<\/td><td>$25.0M<\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><tr><td>\u2014 Pipeline Development<\/td><td>$23.9M<\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><tr><td>\u2014 Software Solutions<\/td><td>$4.9M<\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><tr><td>\u2014 Other Discovery<\/td><td>$2.5M<\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><tr><td><strong>R&amp;D Expenditure<\/strong><\/td><td>$81.4M<\/td><td>$91.9M<\/td><td>\u219311.4%<\/td><\/tr><tr><td><strong>Net Loss<\/strong><\/td><td>$352.3M<\/td><td>$17.1M<\/td><td>\u21911,960%<\/td><\/tr><tr><td><strong>Cash &amp; Bank Balances<\/strong><\/td><td>$393.3M<\/td><td>\u2014<\/td><td>Strong liquidity position<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The sharp increase in net loss was <strong>primarily driven by lower revenue<\/strong>, not higher spending\u2014R&amp;D costs actually fell due to reduced third-party CRO expenses.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-licensing-amp-pipeline-highlights\">Licensing &amp; Pipeline Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Assets Generated<\/strong>: 20+ candidates at <strong>clinical or IND-filing stage<\/strong> via <strong>Pharma.AI<\/strong><\/li>\n\n\n\n<li><strong>Licensing Deals<\/strong>: 7 partnerships with global pharma and healthcare firms<\/li>\n\n\n\n<li><strong>Total Deal Value<\/strong>: Up to <strong>$2.1748 billion<\/strong>, comprising:<\/li>\n\n\n\n<li><strong>Upfront Payments<\/strong>: Up to <strong>$130.3 million<\/strong><\/li>\n\n\n\n<li><strong>Milestone Payments<\/strong>: Up to <strong>$2.0445 billion<\/strong><\/li>\n<\/ul>\n\n\n\n<p>These agreements validate Insilico\u2019s <strong>end-to-end generative AI drug discovery engine<\/strong>, which spans target identification, molecule generation, and preclinical development.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<p>Despite near-term revenue volatility, Insilico maintains:<br><strong>$393.3M in cash<\/strong>\u2014sufficient to fund operations into 2028<br><strong>Asset-heavy model<\/strong>: Focus on high-value proprietary programs vs. low-margin service work<br><strong>Platform defensibility<\/strong>: Pharma.AI integrates generative chemistry, biology, and clinical trial prediction<\/p>\n\n\n\n<p>The company is shifting from <strong>fee-for-service discovery<\/strong> toward <strong>asset-centric value capture<\/strong>, a capital-intensive but higher-upside strategy common among biotech innovators.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Biotech Valuation Reset<\/strong>: The sector faced investor scrutiny in 2025 over monetization timelines<\/li>\n\n\n\n<li><strong>Differentiator<\/strong>: Insilico is among the few AI-native firms with <strong>multiple clinical-stage assets and signed licensing revenue<\/strong><\/li>\n\n\n\n<li><strong>Risk Factor<\/strong>: Milestone payments are contingent on clinical success\u2014only upfronts are guaranteed<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding pipeline progression, milestone realization, and cash runway. Actual results may differ due to clinical trial outcomes, partner decisions, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032900704_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026032900704_c.\"><\/object><a id=\"wp-block-file--media-292c945e-8710-4336-91cd-11f5bfe2741c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032900704_c.pdf\">2026032900704_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032900704_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-292c945e-8710-4336-91cd-11f5bfe2741c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61804,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,4514,164],"class_list":["post-61800","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial results, reporting $56.2 million in total revenue, a 34.5% year-over-year decline, offset by robust cash reserves and continued pipeline advancement. Despite the revenue contraction, the company highlighted that its Pharma.AI platform has generated over 20 clinical- or IND-stage assets, with seven licensed deals totaling up to $2.17 billion in potential value.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61800\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial results, reporting $56.2 million in total revenue, a 34.5% year-over-year decline, offset by robust cash reserves and continued pipeline advancement. Despite the revenue contraction, the company highlighted that its Pharma.AI platform has generated over 20 clinical- or IND-stage assets, with seven licensed deals totaling up to $2.17 billion in potential value.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61800\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-30T06:44:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T06:44:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M\",\"datePublished\":\"2026-03-30T06:44:35+00:00\",\"dateModified\":\"2026-03-30T06:44:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800\"},\"wordCount\":343,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3002.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61800#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61800\",\"name\":\"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3002.webp\",\"datePublished\":\"2026-03-30T06:44:35+00:00\",\"dateModified\":\"2026-03-30T06:44:36+00:00\",\"description\":\"Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial results, reporting $56.2 million in total revenue, a 34.5% year-over-year decline, offset by robust cash reserves and continued pipeline advancement. Despite the revenue contraction, the company highlighted that its Pharma.AI platform has generated over 20 clinical- or IND-stage assets, with seven licensed deals totaling up to $2.17 billion in potential value.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61800\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61800#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial results, reporting $56.2 million in total revenue, a 34.5% year-over-year decline, offset by robust cash reserves and continued pipeline advancement. Despite the revenue contraction, the company highlighted that its Pharma.AI platform has generated over 20 clinical- or IND-stage assets, with seven licensed deals totaling up to $2.17 billion in potential value.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61800","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M","og_description":"Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial results, reporting $56.2 million in total revenue, a 34.5% year-over-year decline, offset by robust cash reserves and continued pipeline advancement. Despite the revenue contraction, the company highlighted that its Pharma.AI platform has generated over 20 clinical- or IND-stage assets, with seven licensed deals totaling up to $2.17 billion in potential value.","og_url":"https:\/\/flcube.com\/?p=61800","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-30T06:44:35+00:00","article_modified_time":"2026-03-30T06:44:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61800#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61800"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M","datePublished":"2026-03-30T06:44:35+00:00","dateModified":"2026-03-30T06:44:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61800"},"wordCount":343,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61800#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3002.webp","keywords":["Finanical Reports","HKG: 3696","Insilico Medicine"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61800#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61800","url":"https:\/\/flcube.com\/?p=61800","name":"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61800#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61800#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3002.webp","datePublished":"2026-03-30T06:44:35+00:00","dateModified":"2026-03-30T06:44:36+00:00","description":"Insilico Medicine (HKG: 3696), a pioneer in generative AI-driven drug discovery, released its 2025 financial results, reporting $56.2 million in total revenue, a 34.5% year-over-year decline, offset by robust cash reserves and continued pipeline advancement. Despite the revenue contraction, the company highlighted that its Pharma.AI platform has generated over 20 clinical- or IND-stage assets, with seven licensed deals totaling up to $2.17 billion in potential value.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61800#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61800"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61800#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3002.webp","width":1080,"height":608,"caption":"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61800#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61800"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61800\/revisions"}],"predecessor-version":[{"id":61805,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61800\/revisions\/61805"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61804"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}